Showing results (1-10 of 238) with videos related to
Sort By:
Pageof 24
Journal of the National Cancer Institute|November 18, 1992
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directionsR J Motzer, G J BoslThe Urologic Clinics of North America|May 1, 1987
Chemotherapy for germ cell tumorsR J Motzer, G J BoslUrology|August 1, 1987
Hemorrhage: a complication of metastatic testicular choriocarcinomaR J Motzer, G J BoslThe Urologic Clinics of North America|February 1, 1993
Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumorsR J Motzer, G J BoslCancer|September 1, 1990
The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patientsR J Motzer, N L Geller, G J BoslInvestigational New Drugs|November 1, 1992
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCTB A Murphy, R J Motzer, G J BoslCancer Treatment Reports|February 1, 1987
Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatinR J Motzer, G J Bosl, K Tauer, et al.Seminars in Oncology|April 1, 1992
Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumorsD F Bajorin, H Herr, R J Motzer, et al.Journal of the National Cancer Institute|October 19, 1994
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol designT C Chou, R J Motzer, Y Tong, et al.Cancer Research|September 15, 1988
Blood group-related antigens in human germ cell tumorsR J Motzer, V E Reuter, C Cordon-Cardo, et al.Pageof 24